AAP
PBYI icon

Arax Advisory Partners’s Puma Biotechnology PBYI Stock Holding History

Arax Advisory Partners’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.6K Sell
1,799
-384
-18% -$2.81K ﹤0.01% 4157
2026
Q1 		$1.34K Buy
2,183
+2,173
+21,730% +$14K ﹤0.01% 3218
2025
Q4 		$60 Sell
10
-1,262
-99% -$6.7K ﹤0.01% 3895
2025
Q3 		$6.75K Buy
+1,272
New +$5.39K ﹤0.01% 2767

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Arax Advisory Partners's PBYI Position: Q2 2026 in Review

Arax Advisory Partners reduced its Puma Biotechnology (PBYI) stake by 18% in Q2 2026, selling an estimated $2.81K and leaving 1,799 shares worth $14.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4157.

Arax Advisory Partners first reported a position in PBYI in Q3 2025 and has held it in 4 quarters since. 161 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Arax Advisory Partners held 1,799 shares of Puma Biotechnology worth $14.6K as of Q2 2026.
  • Arax Advisory Partners sold 384 Puma Biotechnology shares in Q2 2026, an estimated $2.81K.
  • Puma Biotechnology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4157 holding.
  • Arax Advisory Partners first reported a position in Puma Biotechnology in Q3 2025 and has held it in 4 quarters since.
  • 161 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.